Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AtriCure settlement

This article was originally published in The Gray Sheet

Executive Summary

Firm enters "tentative" agreement with the Department of Justice Nov. 4 to settle allegations of illegal off-label promotion of its Isolator cardiac ablation devices for atrial fibrillation treatment. AtriCure proposes to pay $3.8 million, plus interest, over five years and enter into a corporate integrity agreement with the HHS Office of Inspector General. However, AtriCure admits no wrongdoing. The firm's Isolator bipolar ablation system and Coolrail linear ablation device are FDA-cleared for ablating cardiac tissue during surgical procedures, but not specifically for AF. Johnson & Johnson/Biosense Webster's NaviStar ThermoCool catheters remain the only FDA-approved AF ablation catheters on the market. AtriCure was among five companies facing whistleblower lawsuits for off-label promotion of ablation catheters. Medtronic, Boston Scientific and St. Jude Medical are still under investigation, while Endoscopic Technologies settled related allegations in July for $1.4 million (1"The Gray Sheet" July 20, 2009)

You may also be interested in...

CMS Budget Addresses Medicare Fraud, Beefs Up Data Infrastructure

While President Obama's fiscal 2011 budget request does not seek the broad coverage expansions and Medicare reforms pursued by languishing comprehensive health care reform bills, it attempts to make progress around the edges with attention to fighting Medicare fraud and beefing up CMS

DoJ Targets Five Cardiac Ablation Device Makers In False Claims Probe

Medtronic, Boston Scientific, St. Jude Medical and AtriCure are targeted in an ongoing Justice Department probe into alleged off-label promotion of cardiac ablation devices for atrial fibrillation

Axcella Addresses Metabolic Disease Quickly With GRAS Candidates

Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts